Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EPS (Basic): 2022-2025

Historic EPS (Basic) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$0.41.

  • Phathom Pharmaceuticals' EPS (Basic) rose 68.94% to -$0.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.77, marking a year-over-year increase of 34.43%. This contributed to the annual value of -$5.29 for FY2024, which is 34.61% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported EPS (Basic) of -$0.41 as of Q3 2025, which was up 60.95% from -$1.05 recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' EPS (Basic) ranged from a high of -$0.41 in Q3 2025 and a low of -$1.56 during Q2 2024.
  • Its 3-year average for EPS (Basic) is -$1.09, with a median of -$1.05 in 2025.
  • Per our database at Business Quant, Phathom Pharmaceuticals' EPS (Basic) crashed by 85.71% in 2024 and then spiked by 68.94% in 2025.
  • Phathom Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$1.33 in 2022, then declined by 9.02% to -$1.45 in 2023, then spiked by 31.03% to -$1 in 2024, then surged by 68.94% to -$0.41 in 2025.
  • Its EPS (Basic) stands at -$0.41 for Q3 2025, versus -$1.05 for Q2 2025 and -$1.31 for Q1 2025.